HK1231404A1 - 禁食條件下的他司美瓊的施用 - Google Patents

禁食條件下的他司美瓊的施用

Info

Publication number
HK1231404A1
HK1231404A1 HK17105202.4A HK17105202A HK1231404A1 HK 1231404 A1 HK1231404 A1 HK 1231404A1 HK 17105202 A HK17105202 A HK 17105202A HK 1231404 A1 HK1231404 A1 HK 1231404A1
Authority
HK
Hong Kong
Prior art keywords
administration
fasted conditions
under fasted
tasimelteon
tasimelteon under
Prior art date
Application number
HK17105202.4A
Other languages
English (en)
Inventor
Marlene Michelle Dressman
Mihael H Polymeropoulos
Paolo Baroldi
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1231404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of HK1231404A1 publication Critical patent/HK1231404A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK17105202.4A 2014-01-14 2017-05-23 禁食條件下的他司美瓊的施用 HK1231404A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927465P 2014-01-14 2014-01-14
US14/511,669 US10376487B2 (en) 2013-11-12 2014-10-10 Method of treatment
PCT/US2015/010410 WO2015108728A1 (en) 2014-01-14 2015-01-07 Administration of tasimelteon under fasted conditions

Publications (1)

Publication Number Publication Date
HK1231404A1 true HK1231404A1 (zh) 2017-12-22

Family

ID=53520399

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105202.4A HK1231404A1 (zh) 2014-01-14 2017-05-23 禁食條件下的他司美瓊的施用

Country Status (20)

Country Link
US (4) US10376487B2 (zh)
EP (1) EP3094322B1 (zh)
JP (3) JP2017502996A (zh)
KR (3) KR101970050B1 (zh)
CN (2) CN107072978A (zh)
AU (3) AU2015206797A1 (zh)
CA (2) CA2936504C (zh)
CL (1) CL2016001794A1 (zh)
DK (1) DK3094322T3 (zh)
ES (1) ES2805451T3 (zh)
HK (1) HK1231404A1 (zh)
HR (1) HRP20201069T1 (zh)
HU (1) HUE051244T2 (zh)
IL (1) IL246676B (zh)
MX (1) MX2016009231A (zh)
NZ (1) NZ722254A (zh)
PT (1) PT3094322T (zh)
SI (1) SI3094322T1 (zh)
WO (1) WO2015108728A1 (zh)
ZA (1) ZA201605103B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
DK3188727T3 (da) * 2014-09-02 2023-02-06 Vanda Pharmaceuticals Inc Tasimelteon til behandling af smith-magenis¿ syndrom
EP3661494B8 (en) 2017-08-02 2023-11-22 Vanda Pharmaceuticals Inc. Use of tasimelteon for the treatment of affective disorders in majority black african patients
SG11202101828PA (en) * 2018-09-12 2021-04-29 Vanda Pharmaceuticals Inc Improving sleep or post-sleep performance
WO2021119456A1 (en) 2019-12-13 2021-06-17 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof
CA3229930A1 (en) 2021-09-14 2023-03-23 Mihael Polymeropoulos Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
DE3466215D1 (en) 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
IL79264A0 (en) 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US4997845A (en) 1987-02-02 1991-03-05 Eli Lilly And Company β-alkylmelatonins as ovulation inhibitors
US5093352A (en) 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
WO1996023496A1 (en) 1995-02-01 1996-08-08 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
AU713030B2 (en) 1995-10-24 1999-11-18 Gruenenthal Gmbh Method of adjusting the circadian rhythm of a mammal
PL190499B1 (pl) 1996-12-10 2005-12-30 Bristol Myers Squibb Co Pochodna benzodioksolu, benzofuranu, dihydrobenzofuranu lub benzodioksanu, jej zastosowanie i kompozycja farmaceutyczna
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
AUPO588297A0 (en) 1997-03-26 1997-04-24 Luminis Pty Limited Mediation in melatonin production
WO1999063977A2 (en) 1998-06-09 1999-12-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders
US6562858B2 (en) 1999-05-17 2003-05-13 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating depression
PT1189900E (pt) 1999-06-30 2004-05-31 Bristol Myers Squibb Co Derivados de aminopirrolidina heterociclicos utilizados como agentes melatonergicos
EP1441727B1 (en) 2001-10-30 2010-12-29 Novartis AG Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP2005080603A (ja) 2003-09-10 2005-03-31 Kumamoto Technology & Industry Foundation 生体リズム障害の度合の判断方法
WO2005063240A1 (en) 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
JP2007517040A (ja) 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
KR101187461B1 (ko) 2005-07-29 2012-10-02 반다 파마슈티칼즈, 인코퍼레이티드. 각성을 향상시키는 방법
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
CN101448805B (zh) 2006-05-22 2012-12-12 Vanda制药公司 抑郁障碍的治疗
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20080171061A1 (en) 2006-07-21 2008-07-17 Douglas Nixon Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
ES2906582T3 (es) 2007-04-11 2022-04-19 Biomarin Pharm Inc Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida
WO2009036257A1 (en) 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
WO2009084023A2 (en) 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
US20100249164A1 (en) 2007-10-31 2010-09-30 Renger John J Modulation of sleep with nr2b receptor antagonists
JP5558016B2 (ja) 2009-03-17 2014-07-23 株式会社 資生堂 概日リズム調整剤
SG174583A1 (en) 2009-04-07 2011-10-28 Duocort Pharma Ab Improved glucocorticoid therapy
EP2453891A1 (en) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
KR102317399B1 (ko) 2012-01-26 2021-10-26 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015123389A1 (en) 2014-02-12 2015-08-20 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon

Also Published As

Publication number Publication date
EP3094322A1 (en) 2016-11-23
HUE051244T2 (hu) 2021-03-01
AU2020202719A1 (en) 2020-05-14
IL246676A0 (en) 2016-08-31
RU2016133348A3 (zh) 2018-09-26
CN107072978A (zh) 2017-08-18
WO2015108728A1 (en) 2015-07-23
CL2016001794A1 (es) 2017-04-28
EP3094322B1 (en) 2020-04-08
DK3094322T3 (da) 2020-07-20
RU2016133348A (ru) 2018-02-20
ES2805451T3 (es) 2021-02-12
US20150196527A1 (en) 2015-07-16
US20210379008A1 (en) 2021-12-09
AU2015206797A1 (en) 2016-08-04
JP2021102634A (ja) 2021-07-15
PT3094322T (pt) 2020-07-14
JP2023024704A (ja) 2023-02-16
SI3094322T1 (sl) 2020-08-31
CA3091827A1 (en) 2015-07-23
US20200188346A1 (en) 2020-06-18
US10376487B2 (en) 2019-08-13
NZ722254A (en) 2022-07-01
US20190336470A1 (en) 2019-11-07
US11141400B2 (en) 2021-10-12
KR101970050B1 (ko) 2019-04-17
CA2936504A1 (en) 2015-07-23
KR20200106094A (ko) 2020-09-10
US20170087122A9 (en) 2017-03-30
US11786502B2 (en) 2023-10-17
US10610511B2 (en) 2020-04-07
MX2016009231A (es) 2016-10-05
CN116115551A (zh) 2023-05-16
IL246676B (en) 2020-10-29
CA2936504C (en) 2020-10-13
KR102154458B1 (ko) 2020-09-09
AU2020202719B2 (en) 2022-03-10
HRP20201069T1 (hr) 2020-10-30
KR20190040102A (ko) 2019-04-16
ZA201605103B (en) 2023-07-26
AU2022201953A1 (en) 2022-04-14
JP2017502996A (ja) 2017-01-26
KR20160106735A (ko) 2016-09-12
KR102276569B1 (ko) 2021-07-12

Similar Documents

Publication Publication Date Title
IL250511A0 (en) Crystalline forms of ibrutinib
ZA201700880B (en) Polymorphs of selinexor
HK1258062A1 (zh) 給予惡拉戈利的方法
HK1231404A1 (zh) 禁食條件下的他司美瓊的施用
IL252283A0 (en) Sublingual administration of riluzole
SI3845221T1 (sl) Trdne oblike sofosbuvirja
HU4602U (en) Set of saggar assembly
IL246979A0 (en) Crystalline forms of sofosbuvir
PL3180658T3 (pl) Bezpieczna konfiguracja instalacji automatyki domowej
IL285700A (en) 21- Hydroxylation of steroids
HU4603U (en) Set of saggar assembly
IL249130B (en) Preparation of piperidine-4-carbothioamide
TWM490537U (en) Structure of stand
HUE050165T2 (hu) Etilén-glikolok MMF származékai
TWM490377U (en) Improved structure of C clamp
IL249332A0 (en) Crystalline forms of sofosbuvir
ZA201507042B (en) Parenteral dosage form of amiodarone
TWM489230U (en) Improved structure of pin set
GB201417348D0 (en) Prodrugs of lxazomib
GB201417347D0 (en) Prodrugs of delanzomib
GB201405142D0 (en) Theory of restoration
GB201416054D0 (en) Chemotherapy of viruses
GB201402924D0 (en) The theory of instantransmission
TWM490349U (en) Improved structure of a darter
GB201413139D0 (en) Assessment of structures